S. 5059, Regulatory Streamlining (Biosimilar Approval). Quorum's AI analysis reads it as a trade-off: gains for some, costs for others.
S. 5059 · Mixed
What it does
This bill removes one procedural requirement from the FDA's review process for biosimilar drugs—medications designed to copy expensive biologic drugs. It strikes subparagraph (B) of Section 351(k)(5) of the Public Health Service Act and renumbers the remaining provisions. The effect depends entirely on what subparagraph (B) currently requires; without seeing that text, the civic impact cannot be fully assessed, but the bill's stated purpose is to streamline (speed up) FDA approval of biosimilars, which could lower drug costs for patients if it reduces unnecessary delays.
The analysis names biosimilar manufacturers — and 2 more groups — among the beneficiaries.
The trade-off
The bill's civic impact hinges entirely on the content of Section 351(k)(5)(B) of the Public Health Service Act, which is not quoted in this text. If that subparagraph requires comparative clinical efficacy data, its removal could allow biosimilars to reach market with weaker evidence of safety parity. If it is a redundant administrative step, removal is benign.
The analysis put a high warning level on this bill. Transparency scores 30%, and the analysis found no provisions unrelated to the bill's subject.
Who is behind it
Filed by Ashley Moody. Cosponsored by Angela Alsobrooks, Lisa Blunt Rochester and Rick Scott.